{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T23:23:47Z","timestamp":1777418627242,"version":"3.51.4"},"reference-count":27,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2010,2,23]],"date-time":"2010-02-23T00:00:00Z","timestamp":1266883200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2010,3]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To review pitavastatin, the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor and determine its place in the treatment of hypercholesterolemia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Sources:<\/jats:title>\n                    <jats:p>Literature was accessed through PubMed (1948\u2013December 2009). Pitavastatin, itavastatin, nisvastatin, NK 104, and NKS 104 were used as search terms. Results were limited to articles written in the English language.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study Selection And Data Extraction:<\/jats:title>\n                    <jats:p>All articles identified from the data source were reviewed for inclusion. Articles included were those pertaining to the pharmacology and pharmacokinetic properties of pitavastatin, in addition to original research evaluating the clinical efficacy of pitavastatin for hypercholesterolemia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Synthesis:<\/jats:title>\n                    <jats:p>Pitavastatin is an oral HMG-CoA reductase inhibitor recently approved by the Food and Drug Administration for the treatment of primary hyperlipidemia and mixed dyslipidwmia. Pitavastatin 2 mg has been shown to be noninferior to atorvastatin 10 mg and simvastatin 20 mg with respect to low-density lipoprotein cholesterol (LDL-C)\u2013lowering ability. Additionally, pitavastatin 2 mg was shown in one study to lower LDL-C significantly more than pravastatin 10 mg. As with other HMG-CoA reductase inhibitors, primary safety concerns are related to myopathies and alterations in liver enzyme levels. While efficacy regarding beneficial effects on lipid parameters is comparable to that of other agents, a potential advantage of pitavastatin is its cytochrome P450 (CYP450) independent elimination, thereby reducing the likelihood of clinically significant drug-drug interactions. However, this is not a unique property, as pravastatin and rosuvastatin also possess this property.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>In light of the lack of outcome data, pitavastatin offers no clear advantage over other drugs in this class.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1345\/aph.1m624","type":"journal-article","created":{"date-parts":[[2010,2,23]],"date-time":"2010-02-23T22:18:50Z","timestamp":1266963530000},"page":"507-514","source":"Crossref","is-referenced-by-count":19,"title":["New Drug Approvals: Pitavastatin: A New HMG-CoA Reductase Inhibitor"],"prefix":"10.1177","volume":"44","author":[{"given":"Terri M","family":"Wensel","sequence":"first","affiliation":[{"name":"McWhorter School of Pharmacy, Samford University, Birmingham, AL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruce A","family":"Waldrop","sequence":"additional","affiliation":[{"name":"McWhorter School of Pharmacy, Samford University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"Wensel","sequence":"additional","affiliation":[{"name":"DCH Regional Medical Center, Tuscaloosa, AL"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2010,2,23]]},"reference":[{"key":"bibr1-aph.1M624","volume-title":"Livalo (pitavastatin)","author":"Product information.","year":"2009"},{"key":"bibr2-aph.1M624","doi-asserted-by":"publisher","DOI":"10.1177\/009127002401102731"},{"key":"bibr3-aph.1M624","unstructured":"FDA\/CDER resources page. Food and Drug Administration. www.fda.gov\/cder\/approval\/index.him (accessed 2009 Dec 4)."},{"key":"bibr4-aph.1M624","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2005.00461.x"},{"key":"bibr5-aph.1M624","volume-title":"Mevacor (lovastatin)","author":"Product information.","year":"2008"},{"key":"bibr6-aph.1M624","volume-title":"Zocor (simvastatin)","author":"Product information.","year":"2008"},{"key":"bibr7-aph.1M624","volume-title":"Pravachol (pravastatin)","author":"Product information.","year":"2007"},{"key":"bibr8-aph.1M624","volume-title":"Lipitor (atorvastatin)","author":"Product information.","year":"2009"},{"key":"bibr9-aph.1M624","volume-title":"Lescol, Lescol XL (fluvastatin)","author":"Product information.","year":"2006"},{"key":"bibr10-aph.1M624","volume-title":"Crestor (rosuvastatin)","author":"Product information.","year":"2009"},{"key":"bibr11-aph.1M624","doi-asserted-by":"publisher","DOI":"10.1126\/science.3513311"},{"key":"bibr12-aph.1M624","doi-asserted-by":"publisher","DOI":"10.1016\/j.clpt.2005.07.003"},{"key":"bibr13-aph.1M624","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.104.068056"},{"key":"bibr14-aph.1M624","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-006-9159-2"},{"key":"bibr15-aph.1M624","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2009.04.053"},{"key":"bibr16-aph.1M624","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0801936"},{"key":"bibr17-aph.1M624","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2006.03.003"},{"key":"bibr18-aph.1M624","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2005.02462.x"},{"key":"bibr19-aph.1M624","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9150(01)00712-2"},{"key":"bibr20-aph.1M624","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2005.07.007"},{"key":"bibr21-aph.1M624","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2007.11.002"},{"key":"bibr22-aph.1M624","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2008.02.008"},{"key":"bibr23-aph.1M624","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2008.05.017"},{"key":"bibr24-aph.1M624","unstructured":"National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Final Report, 2002. www.nhlbi.nih.gov\/guidelines\/cholesterol\/atp3full.pdf (accessed 2009 Nov 30)."},{"key":"bibr25-aph.1M624","unstructured":"Lexi-comp. www.crlonline.com.ezproxy.samford.edu\/crlsql\/servlet\/crlonline (accessed 2009 Oct 8)."},{"key":"bibr26-aph.1M624","volume-title":"Press releases"},{"key":"bibr27-aph.1M624","volume-title":"Red Book: pharmacy's fundamental reference","year":"2009"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1345\/aph.1M624","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1345\/aph.1M624","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:07:28Z","timestamp":1777374448000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1345\/aph.1M624"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,2,23]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,3]]}},"alternative-id":["10.1345\/aph.1M624"],"URL":"https:\/\/doi.org\/10.1345\/aph.1m624","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,2,23]]}}}